Delivery Order SPE2DB22D3004-SPE2DB25FSA17
- Not listed
- The Defense Logistics Agency awarded a $2,599.62 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml) on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single delivery order against AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $34,013.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a medication used to treat cystic fibrosis. This is a non-set-aside competitive award with an ultimate completion date of July 15, 2025, and performance to be conducted at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product commonly used in cystic fibrosis treatment. This non-set-aside, firm fixed-price delivery order has a ceiling value of $16,287.62 and an ultimate completion date of August 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml units) with a ceiling value of $12,701.74. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 27, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $13,882.26 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/mL ampules (2.5 mL) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a discrete delivery of this specialty...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Pulmozyme 1 mg/mL ampules (2.5 mL) at a ceiling value of $6,286.98. This firm fixed-price delivery order, with an ultimate completion date of July 24, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor. The performance location is...
- The Defense Logistics Agency awarded a $9.68K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampules (2.5 mL units) on July 23, 2025, with completion expected by July 24, 2025. This is a firm fixed-price, non-set-aside contract performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99M vehicle extending through...
- The Defense Logistics Agency awarded a delivery order valued at $6,018.36 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml units) on August 21, 2025, with an ultimate completion date of August 22, 2025. The contract employs firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $10,334.40 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in respiratory care. This firm fixed-price delivery order, awarded on July 17, 2025, with an ultimate completion date of July 18, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 20, 2025, for the supply of Pulmozyme 1 mg/mL ampul 2.5mL with a ceiling value of $4,280.40. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and is scheduled for ultimate completion on May 21, 2025. This delivery order is...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FSA17Delivery Order
The Defense Logistics Agency awarded a $5,167.20 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml units) under a firm fixed-price contract with an ultimate completion date of August 18, 2025. This non-set-aside award represents a purchase order for a respiratory medication commonly used in the treatment of cystic fibrosis and is being delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. The contract was awarded on August 15, 2025, and operates as a child delivery order within the larger federal procurement framework. This delivery order flows from AmerisourceBergen Drug Corp's broader relationship with the Defense Logistics Agency, particularly through its significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999.999 billion through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen regularly fulfills competitively awarded supply contracts supporting military and veteran healthcare systems. The company's extensive portfolio with DLA demonstrates its capability to supply a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 8/15/25 |